Search
Biofrontera Inc
BFRIAdd to Watchlist
1.010USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
11.76MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+6.70%
1 Month
-1.94%
6 Months
+39.31%
Year to Date
+77.19%
1 Year
+46.36%
Key Figures
1.020Open
1.065High
394.50KVolume
LossP/E TTM
2.12P/E Dynamic
--Dividend TTM
3.39%Turnover Ratio
1.010Prev. Close
1.000Low
296.17KTurnover
LossP/E Static
-4.56P/B
0.00%Div Yield TTM
-53.58%ROA
1.19052wk High
2.25Volume Ratio
-17.76MNet Profit
11.65MShares
-0.9689EPS TTM
0.85Beta
-339.04%ROE
0.53652wk Low
6.44%Amplitude
79.02%Gross Margin
11.76MMarket Cap
0.49Reward/Risk
5.04%Risk Rate
TradingKey Stock Score of Biofrontera Inc
Currency: USD Updated: 2026-07-02Key Insights
Biofrontera Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 99 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biofrontera Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Biofrontera Inc Highlights
StrengthsRisks
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.41% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.70M.
Undervalued
The company’s latest PE is -1.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.75M shares, decreasing 9.14% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+488.24%
Upside Space
Biofrontera Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biofrontera Inc Info
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Ticker SymbolBFRI
CompanyBiofrontera Inc
CEOLuebbert (Hermann)
Websitehttps://www.biofrontera-us.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14968.000
+165.000 (+1.11%)
69676.000
+1528.000 (+2.24%)
6410.400
+57.600 (+0.91%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Biofrontera Inc (BFRI)?
The current price of Biofrontera Inc (BFRI) is 1.01.
What is the symbol of Biofrontera Inc?
The ticker symbol of Biofrontera Inc is BFRI.
What is the 52-week high of Biofrontera Inc?
The 52-week high of Biofrontera Inc is 1.19.
What is the 52-week low of Biofrontera Inc?
The 52-week low of Biofrontera Inc is 0.54.
What is the market capitalization of Biofrontera Inc?
The market capitalization of Biofrontera Inc is 12.93M.
Is Biofrontera Inc (BFRI) currently rated as Buy, Hold, or Sell?
According to analysts, Biofrontera Inc (BFRI) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI)?
The Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI) is -1.04.